1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Accord Follows US Approval With EU Nod On Ustekinumab

Two Versions Of Stelara Biosimilar Approved As Absimky And Imuldosa

 
• By Dave Wallace

Accord has received a nod from the EMA for its Stelara biosimilar, while Neuraxpharm has seen a buprenorphine hybrid film endorsed and Viatris has received a positive CHMP opinion for an eltrombopag generic.

The CHMP endorsed several new products at its October meeting (Shutterstock)

The latest meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use has resulted in positive opinions for Accord Healthcare’s Stelara (ustekinumab) biosimilar as well as a buprenorphine hybrid film for Neuraxpharm and an eltrombopag generic for Viatris.

While CHMP positive opinions do not constitute formal approval, the European Commission typically acts within 67 days to convert

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Generics